Trial Profile
A Pilot Study to Evaluate the Efficacy and Safety of Secukinumab in the Treatment of Moderate to Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- 16 May 2020 Results published in the Journal of Allergy and Clinical Immunology
- 16 May 2020 Primary endpoint (Change in epidermal thickness of lesional skin)has not been met, as per Results published in Journal of Allergy and Clinical Immunology
- 20 Aug 2018 Status changed from recruiting to completed.